Nasal spray mumps vaccine trial launches in healthy young adults
NCT ID NCT06967181
First seen Jan 06, 2026 · Last updated May 05, 2026 · Updated 16 times
Summary
This early-stage trial tests two new nasal spray vaccines (CVM150 and CVM26) designed to prevent mumps. About 60 healthy adults aged 18-29 will receive one of the vaccines to check for side effects and measure immune response. The goal is to find a safer, easier-to-use alternative to current shots.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUMPS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Children's Hospital Medical Center Vaccine Research Center
Cincinnati, Ohio, 45229, United States
-
Coastal Carolina Research Center
North Charleston, South Carolina, 29405, United States
-
University Of Rochester Medical Center
Rochester, New York, 14642, United States
Conditions
Explore the condition pages connected to this study.